Yuting Yan, Ph.D.

626-218-5628
Yuting Yan, Ph.D.
Visiting Scholar, Department of Systems Biology
Research Area
  • Understand MCL Biology Through Integrated Genome and Transcriptome Analysis
  • Clonal Heterogeneity and Evolution Under Therapy Pressure in Multiple Myeloma
Research Teams
Systems Biology
Yuting Yan, Ph.D., is a visiting scholar in Lili Wang's Lab in the Department of Systems Biology at City of Hope.

Location

Education & Experience

Degrees

  • 2018-present, Ph.D. Candidate, Peking Union Medical College, State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital

  • 2015-2018, M.S. Clinical Hematology, Peking Union Medical College, Institute of Hematology and Blood Disease Hospital

  • 2010-2015, M.D. Southern Medical University, Guangzhou, China

Fellowship

  • 2018-2020, Fellowship Programs, Peking Union Medical College, Institute of Hematology and Blood Disease Hospital, China

Residency

  • 2015-2018, Residency Program, Tianjin Medical University General Hospital, China

Professional Experience

  • 2020-present, Visiting Scholar, Department of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA

Awards & Memberships

Awards

  • 2019, American Society of Hematology (ASH) Abstract Achievement Award of 61st ASH Annual Meeting

  • 2019, IMS Award for Exemplary Abstract of 17th International Myeloma Workshop Organizing Committee

  • 2019, Top Ten Youth Awards, Institute of Hematology and Blood Disease Hospital

  • 2018, The First place of Excellent presentation of The Sixth National Academic Conference On Hematologic Oncology, Chinese Anti-Cancer Association

  • 2017, Excellent Graduate Students of Peking Union Medical College

  • 2017, National Scholarship of Excellent Postgraduate Student

  • 2016, The First Prize Scholarship of Peking Union Medical College

Publications

Du C, Mao X, Xu Y, Yan Y, Yuan C, Du X, Liu J, Fan H, Wang Q, Sui W, Deng S, Fu M, Li Z, Li C, Zhao J, Yi S, Liu L, Hao M, Zou D, Zhao Y, Qiu L, An G. 1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomib. Leuk Lymphoma. 2020;61(5):1201-1210.
 
Yan Y, Lv, Xiong W, Li Z, Wang Y, Yu Y, Yu Z, Wang T, Sui W, Liu W, Zou D, Yi S, Qiu L. Subtype distribution, clinical features and survival in B-cell chronic lymphoproliferative disorders in China: a review of 1592 cases, Clinical Lymphoma, Myeloma and Leukemia, 2019 7. pii: S2152-2650(19)32099-3.
 
Yi# S, Yan# Y, Xiong W, Lv R, Yu Z, Liu W, Liu E, Li H, Liu H, Li Z, An G,  Xu Y, Ru K, Zou D, Qiu L. Distinct clinical characteristics draw a new prognostic model for splenic marginal zone lymphoma in HBV high prevalent region, Oncotarget, 2017 19;8(58):98757-98770. (Equal contributor)
 
Yan Y, Mao X, Liu J,  Fan H, Du C, Li Z, Yi S, Wang T, Lv R, Liu W, Deng S, Sui W, Wang Q, Zou D, Cheng T, Zhan F, Tai Y-T, Qiu L, Anderson KC, Gang A. The impact of response kinetics for multiple myeloma in the era of novel agents. Blood Advances. 2019 8;3(19):2895-2904.
 
An# G, Yan# Y, Xu Y, Mao X, Liu J, Fan H, Wang Q, Du C, Li Z, Yi S, Lv R, Deng S, Sui W, Fu M, Hao M, Huang W, Zou D,  zhao Y, Cheng T, Tai Y-T, Munshi N, Qiu L. Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma. Leukemia, 2020;34(2):578-588. (Equal contributor)